Disease-specific IgG Fc N-glycosylation as personalized biomarkers to differentiate gastric cancer from benign gastric diseases

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhang, Dan ^a   Chen, Bingchao ^b   Wang, Yanmin ^b   Xia, Peng ^c   He, Chengyan ^d   Liu, Yujie ^a   Zhang, Ruiqing ^a   Zhang, Mo ^a   Li, Zhili ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b Heze Municipal Hospital   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; TUMOR MARKER;

ADULT; AGED; BLOOD; CHEMISTRY; FEMALE; GLYCOSYLATION; HUMAN; MALE; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PERSONALIZED MEDICINE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STOMACH TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ASPARAGINE; BIOMARKERS, TUMOR; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PRECISION MEDICINE; ROC CURVE; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84975217580     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25957     Document Type: Article

References (52)

1. Carter, D. New Global Survey Shows an Increasing Cancer Burden. AJN The American Journal of Nursing 114, 17-17 (2014).
2. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J Clin 65, 87-108 (2015).
3. Arnold, M. et al. The burden of stomach cancer in indigenous populations: a systematic review and global assessment. Gut 63, 64-71 (2014).
4. Maconi, G., Manes, G. & Porro, G. B. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol 14, 1149-1155 (2008).
5. Imperiali, B. & O'Connor, S. E. Effect of N-linked glycosylation on glycopeptide and glycoprotein structure. Curr Opin Chem Biol 3, 643-649 (1999).
6. Knezevic, A. et al. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology 20, 959-969 (2010).
7. Callewaert, N. et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10, 429-434 (2004).
8. Kellokumpu, S., Sormunen, R. & Kellokumpu, I. Abnormal glycosylation and altered Golgi structure in colorectal cancer: dependence on intra-Golgi pH. FEBS Lett 516, 217-224 (2002).
9. Stowell, S. R., Ju, T. & Cummings, R. D. Protein glycosylation in cancer. Annu Rev Pathol 10, 473-510 (2015).
10. Mechref, Y. et al. Defining putative glycan cancer biomarkers by MS. Bioanalysis 4, 2457-2469 (2012).
11. Kirmiz, C. et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics 6, 43-55 (2007).
12. Ozcan, S. et al. Serum glycan signatures of gastric cancer. Cancer Prev Res (Phila) 7, 226-235 (2014).
13. Li, L. et al. The diagnostic value of serum fucosylated fetuin A in hepatitis B virus-related liver diseases. Clin Chem Lab Med 54, 693-710 (2015).
14. Chrostek, L. et al. Sialic acid level reflects the disturbances of glycosylation and acute-phase reaction in rheumatic diseases. Rheumatol Int 34, 393-399 (2014).
15. Varadi, C. et al. Analysis of haptoglobin N-glycome alterations in inflammatory and malignant lung diseases by capillary electrophoresis. Electrophoresis 34, 2287-2294 (2013).
16. Plomp, R. et al. Site-Specific N-Glycosylation Analysis of Human Immunoglobulin E. J Proteome Res 13, 536-546 (2013).
17. Parekh, R. B. et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316, 452-457 (1985).
18. Fujii, S. et al. Structural heterogeneity of sugar chains in immunoglobulin G. Conformation of immunoglobulin G molecule and substrate specificities of glycosyltransferases. J Biol Chem 265, 6009-6018 (1990).
19. Umana, P. et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17, 176-180 (1999).
20. Raju, T. S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Current opinion in immunology 20, 471-478 (2008).
21. Selman, M. H. et al. IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. J Proteome Res 10, 143-152 (2011).
22. Perdivara, I. et al. Mass spectrometric determination of IgG subclass-specific glycosylation profiles in siblings discordant for myositis syndromes. J Proteome Res 10, 2969-2978 (2011).
23. Fokkink, W. J. et al. IgG Fc N-glycosylation in Guillain-Barre syndrome treated with immunoglobulins. J Proteome Res 13, 1722-1730 (2014).
24. Huffman, J. E. et al. Comparative performance of four methods for high-throughput glycosylation analysis of immunoglobulin G in genetic and epidemiological research. Mol Cell Proteomics 13, 1598-1610 (2014).
25. Irani, V. et al. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol 67, 171-182 (2015).
26. Wang, Y. et al. Elevated serum levels of circulating immunoinflammation-related protein complexes are associated with cancer. J Proteome Res 13, 710-719 (2014).
27. Liu, Y. J., Zhang, D., Cheng, Y. H. & Li, Z. L. Elevated serum immunoinflammation-related protein complexes are associated with psychosis. Psychiat Res 230, 96-101 (2015).
28. Song, G. G. et al. Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib. Clin Chim Acta 440, 44-48 (2015).
29. Webb-Robertson, B. J. M. et al. Review, Evaluation, and Discussion of the Challenges of Missing Value Imputation for Mass Spectrometry-Based Label-Free Global Proteomics. J Proteome Res 14, 1993-2001 (2015).
30. Kuroda, Y. et al. Structural studies on IgG oligosaccharides of patients with primary Sjogren's syndrome. Glycoconj J 19, 23-31 (2002).
31. Kuroda, Y. et al. Structural alterations in outer arms of IgG oligosaccharides in patients with Werner syndrome. Exp Gerontol 42, 545-553 (2007).
32. Chen, G. et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J Proteomics 75, 2824-2834 (2012).
33. Chen, G. et al. Change in IgG Fc N-linked glycosylation in human lung cancer: Age and sex-related diagnostic potential. Electrophoresis 34, 2407-2416 (2013).
34. Yuan, W. et al. Quantitative analysis of immunoglobulin subclasses and subclass specific glycosylation by LC-MS-MRM in liver disease. J Proteomics 116, 24-33 (2015).
35. Kodar, K. et al. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J 29, 57-66 (2012).
36. Parekh, R. et al. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med 167, 1731-1736 (1988).
37. Shikata, K. et al. Structural changes in the oligosaccharide moiety of human IgG with aging. Glycoconj J 15, 683-689 (1998).
38. Castelo-Branco, C. & Soveral, I. The immune system and aging: a review. Gynecol Endocrinol 30, 16-22 (2014).
39. Papadea, C. & Check, I. J. Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic, and clinical aspects. Crit Rev Clin Lab Sci 27, 27-58 (1989).
40. Xue, J., Zhu, L. P. & Wei, Q. IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease. Glycoconj J 30, 735-745 (2013).
41. Murphy, M. A., O'Leary, J. J. & Cahill, D. J. Assessment of the humoral immune response to cancer. J Proteomics 75, 4573-4579 (2012).
42. Malhotra, R. et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannosebinding protein. Nat Med 1, 237-243 (1995).
43. Saldova, R. et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 17, 1344-1356 (2007).
44. Trbojevic Akmacic, I. et al. Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin g glycome. Inflamm Bowel Dis 21, 1237-1247 (2015).
45. Karsten, C. M. et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fc gamma RIIB and dectin-1. Nat Med 18, 1401-+ (2012).
46. Scallon, B. J. et al. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44, 1524-1534 (2007).
47. Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006).
48. Zou, G. et al. Chemoenzymatic synthesis and Fcgamma receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcgammaIIIa receptor. J Am Chem Soc 133, 18975-18991 (2011).
49. Shinkawa, T. et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278, 3466-3473 (2003).
50. Wuhrer, M. et al. Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J Proteome Res 8, 450-456 (2009).
51. Dempster, A. P., Laird, N. M. & Rubin, D. B. Maximum Likelihood from Incomplete Data via the EM Algorithm. Journal of the Royal Statistical Society. Series B (Methodological) 39, 1-38 (1977).
52. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological) 57, 289-300 (1995).